Urachal Cancer
Symptoms, Doctors, Treatments, Advances & More

Urachal Cancer Overview

Save information for later
Sign Up

Learn About Urachal Cancer

What is the definition of Urachal Cancer?
Urachal cancer is a are type of bladder cancers. The urachus is a structure normally only present during development in the womb that connects the bellybutton and the bladder. This connection normally disappears before birth, but in some people remains. Urachal cancers are usually diagnosed in adults in their 50's and 60's and may develop at the dome or anterior wall of the bladder, along the midline of the body (including the belly button), and between the pubis symphasis and the bladder. Most Urachal cancers are adenocarcinomas (cancers that develop from gland cells). Others may be sarcomas (which develop from connective tissue - such as leiomyosarcoma, rhabdomyosarcoma, and malignant fibrous histiocytoma), small cell carcinomas, transitional cell cancer, and mixed neoplasias. Most individuals with Urachal cancer have symptoms of with hematuria (blood in urine). Other symptoms may include abdominal pain, a palpable abdominal mass, mucinuria, and bacteriuria.
What are the alternative names for Urachal Cancer?
  • Urachal cancer
  • Urachal carcinoma
Who are the top Urachal Cancer Local Doctors?
Elite in Urachal Cancer
Elite in Urachal Cancer
Referral may be required
Budapest, BU, HU 

Attila Szendroi practices practicing medicine in Budapest, Hungary. Mr. Szendroi is rated as an Elite expert by MediFind in the treatment of Urachal Cancer. He is also highly rated in 1 other condition, according to our data. His clinical expertise encompasses Urachal Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, Bladder Reconstruction, and Cystectomy.

Elite in Urachal Cancer
Elite in Urachal Cancer
Referral may be required
Essen, NW, DE 

Henning Reis practices practicing medicine in Essen, Germany. Mr. Reis is rated as an Elite expert by MediFind in the treatment of Urachal Cancer. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Urachal Cancer, Bladder Cancer, Urothelial Cancer, Cystectomy, and Prostatectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Urachal Cancer
Elite in Urachal Cancer
Referral may be required
Budapest, BU, HU 

Tibor Szarvas practices practicing medicine in Budapest, Hungary. Mr. Szarvas is rated as an Elite expert by MediFind in the treatment of Urachal Cancer. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Urachal Cancer, Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy.

View All Doctors
What are the latest Urachal Cancer Clinical Trials?
Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors
Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies: A Multicenter, Single-Arm, Phase II Study With Multiple Cohorts
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies: A Multicenter, Single-Arm, Phase II Study With Multiple Cohorts
Enrollment Status: Recruiting
Publish Date: December 30, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: This study is a single-center, multi-cohort, phase II clinical trial. Eligible patients with HER2-positive advanced solid tumors were enrolled after providing informed consent. A total of 90 patients were allocated into three cohorts (30 patients each): those with Extramammary Paget's Disease (EMPD), rare solid tumors, or urothelial carcinoma, who had experienced failure of standard treatment or f...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center